Jacobio Pharmaceuticals Group Co Ltd
HKEX:1167

Watchlist Manager
Jacobio Pharmaceuticals Group Co Ltd Logo
Jacobio Pharmaceuticals Group Co Ltd
HKEX:1167
Watchlist
Price: 1.54 HKD Market Closed
Market Cap: 1.2B HKD
Have any thoughts about
Jacobio Pharmaceuticals Group Co Ltd?
Write Note

Jacobio Pharmaceuticals Group Co Ltd
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Jacobio Pharmaceuticals Group Co Ltd
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Jacobio Pharmaceuticals Group Co Ltd
HKEX:1167
Operating Income
-ÂĄ408.2m
CAGR 3-Years
N/A
CAGR 5-Years
-31%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Operating Income
-ÂĄ8.8B
CAGR 3-Years
8%
CAGR 5-Years
-13%
CAGR 10-Years
N/A
Akeso Inc
HKEX:9926
Operating Income
ÂĄ2B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Operating Income
ÂĄ1.4B
CAGR 3-Years
22%
CAGR 5-Years
55%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Operating Income
ÂĄ2.3B
CAGR 3-Years
31%
CAGR 5-Years
46%
CAGR 10-Years
23%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Operating Income
ÂĄ4.3B
CAGR 3-Years
-27%
CAGR 5-Years
11%
CAGR 10-Years
42%
No Stocks Found

Jacobio Pharmaceuticals Group Co Ltd
Glance View

Market Cap
1.2B HKD
Industry
Biotechnology

Jacobio Pharmaceuticals Group Co., Ltd. operates as an investment holding company which engages in research and development of new drugs. The company is headquartered in Beijing, Beijing. The company went IPO on 2020-12-21. The firm is primarily responsible for the independent discovery and development of innovative tumor therapies. The firm's main drug development projects include JAB-3068 and JAB-3312 clinical stage allosteric SHP2 inhibitors. The firm mainly conducts business within the domestic market.

Intrinsic Value
0.89 HKD
Overvaluation 42%
Intrinsic Value
Price

See Also

What is Jacobio Pharmaceuticals Group Co Ltd's Operating Income?
Operating Income
-408.2m CNY

Based on the financial report for Dec 31, 2023, Jacobio Pharmaceuticals Group Co Ltd's Operating Income amounts to -408.2m CNY.

What is Jacobio Pharmaceuticals Group Co Ltd's Operating Income growth rate?
Operating Income CAGR 5Y
-31%

Over the last year, the Operating Income growth was 14%.

Back to Top